DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025

Group 1 - The core issue involves a securities fraud investigation against Spectrum Pharmaceuticals, Inc. related to misleading statements about its Pinnacle Study for the drug poziotinib, aimed at lung cancer treatment [3] - The class action lawsuit pertains to investors who acquired Spectrum shares between March 17, 2022, and September 22, 2022, during which the company faced significant challenges [1][2] - Spectrum's shares were delisted following its merger with Assertio Holdings, Inc., indicating potential financial instability and regulatory scrutiny [3] Group 2 - Investors have a deadline of September 24, 2025, to seek appointment as lead plaintiff representatives in the class action [2] - Berger Montague PC, a law firm with extensive experience in securities class action litigation, is leading the investigation on behalf of affected investors [5]